Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
Anxiety Disorders, Somatoform Disorders
About this trial
This is an interventional treatment trial for Anxiety Disorders focused on measuring Body Dysmorphic Disorder, Escitalopram, Lexapro, BDD, Body Image
Eligibility Criteria
Inclusion Criteria: Outpatient men and women age 18 and older Diagnosis of BDD within 6 months of study start date based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Score of 24 or higher on the BDD-Yale-Brown Obsessive Compulsive Scale Lives within driving distance of Boston, MA or Providence, RI Exclusion Criteria: Suicidal or homicidal tendencies Alcohol/drug abuse or dependence within 3 months of study entry
Sites / Locations
- Massachusetts General Hospital
- Rhode Island Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Escitalopram
Placebo
In Phase I, all participants received open-label escitalopram for 14 weeks (at a dosage of 10 mg/d in weeks 1-3, 20 mg/d weeks 4-6, and 30 mg/d thereafter). Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to continue with escitalopram for Phase II of the study (Weeks 16-40)
Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to receive a placebo for Phase II of the study (Weeks 16-40)